Loading...
XLON
EKF
Market cap136mUSD
Oct 09, Last price  
26.00GBP
1D
0.00%
1Q
-6.25%
Jan 2017
40.15%
IPO
-38.28%
Name

EKF Diagnostics Holdings PLC

Chart & performance

D1W1MN
XLON:EKF chart
P/E
52.73
P/S
2.17
EPS
0.00
Div yield, %
—
Shrs. gr., 5y
-0.45%
Rev. gr., 5y
-4.60%
Revenues
52m
+2.73%
3,077,000341,000465,00006,483,00021,658,00026,060,00031,804,00040,062,00030,045,00038,589,00041,584,00042,543,00044,917,00065,260,00081,836,00066,635,00052,611,00050,194,00051,564,000
Net income
2m
-66.00%
596,000465,000-1,307,000-203,000-3,435,000-2,884,0001,830,000-1,126,000-5,689,000-37,123,000-18,0002,715,00010,110,0003,678,00011,114,00015,851,000-10,101,0002,352,0006,242,0002,122,000
CFO
10m
-28.92%
-826,000577,000-647,000-676,000-1,409,000-806,0001,599,0002,007,000-4,744,000-4,285,0008,943,0009,053,0008,323,0005,100,00013,809,00010,238,0009,688,0006,311,00013,656,0009,707,000
Dividend
Nov 02, 20231.2 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

EKF Diagnostics Holdings plc, a company founded in 1990 and based in Cardiff, United Kingdom, operates as an international supplier of diagnostic solutions. The firm excels in the development, manufacturing, and distribution of a wide array of diagnostic instruments, chemical reagents, and associated products. Its extensive market reach spans across Europe, the Middle East, the Americas, Asia, Africa, and beyond. The company's product lineup addresses various critical diagnostic needs. This includes a range of hemoglobin analysis devices, such as the handheld DiaSpect Tm and the quantitative Hemo Control. EKF also provides advanced glucose and lactate analyzers like the Biosen C-Line series, alongside point-of-care solutions for diabetes management, exemplified by the Quo-Lab A1c and Quo-Test A1c. Beyond these, their offerings extend to specialized diagnostic tools: the Creamatocrit Plus for assessing lipid concentration in mothers' milk, QuPID and True20 pregnancy tests, and the STAT-Site M Beta-hydroxybutyrate analyzer. EKF further supplies a comprehensive suite of clinical chemical analyzers and reagents, designed for monitoring conditions such as ketosis, glycated albumin, glycated serum protein, and utilizing markers like Procalcitonin for bacterial infections and sepsis. Additional provisions include immunoassay kits, general chemistry analyzers like the Altair 240, micro centrifuges, the Uri-Trak 120 urine analyzer, and dedicated kits and services for COVID-19. The company also offers its manufacturing capabilities as contract solutions to third-party businesses and delivers professional laboratory services.

Key people

Non-Executive Chairman of the Board · since 2016
Non-Executive Deputy Chairman of the Board · since 2015
Richard Anthony Evans
Finance Director, Chief Operating Officer, Executive Director · since 2015
Julian Huw Baines
Chief Executive Officer, Executive Director · since 2009
Carl Dominic Contadini
Non-Executive Director · since 2016
Independent Non-Executive Director · since 2009
IPO date
Jun 05, 2002
Employees
356
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
AVON HOUSE
19 STANWELL ROAD
PENARTH, CRF CF64 2EZ
GB
Previous name
INTERNATIONAL BRAND LICENSING PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT